You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
|
|---|---|
| Published in |
The Lancet, March 2013
|
| DOI | 10.1016/s0140-6736(12)61767-x |
| Pubmed ID | |
| Authors |
John J Bissler, J Christopher Kingswood, Elżbieta Radzikowska, Bernard A Zonnenberg, Michael Frost, Elena Belousova, Matthias Sauter, Norio Nonomura, Susanne Brakemeier, Petrus J de Vries, Vicky H Whittemore, David Chen, Tarek Sahmoud, Gaurav Shah, Jeremie Lincy, David Lebwohl, Klemens Budde |
| Abstract |
Angiomyolipomas are slow-growing tumours associated with constitutive activation of mammalian target of rapamycin (mTOR), and are common in patients with tuberous sclerosis complex and sporadic lymphangioleiomyomatosis. The insidious growth of these tumours predisposes patients to serious complications including retroperitoneal haemorrhage and impaired renal function. Everolimus, a rapamycin derivative, inhibits the mTOR pathway by acting on the mTOR complex 1. We compared the angiomyolipoma response rate on everolimus with placebo in patients with tuberous sclerosis or sporadic lymphanioleiomyomatosis-associated angiomyolipomata. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 31% |
| Spain | 1 | 8% |
| Serbia | 1 | 8% |
| Germany | 1 | 8% |
| United Kingdom | 1 | 8% |
| Italy | 1 | 8% |
| Unknown | 4 | 31% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 62% |
| Practitioners (doctors, other healthcare professionals) | 3 | 23% |
| Scientists | 2 | 15% |
Mendeley readers
The data shown below were compiled from readership statistics for 280 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 2 | <1% |
| France | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| United Kingdom | 1 | <1% |
| Taiwan | 1 | <1% |
| Japan | 1 | <1% |
| United States | 1 | <1% |
| Poland | 1 | <1% |
| Unknown | 271 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 39 | 14% |
| Other | 32 | 11% |
| Student > Bachelor | 28 | 10% |
| Student > Doctoral Student | 24 | 9% |
| Student > Master | 23 | 8% |
| Other | 79 | 28% |
| Unknown | 55 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 133 | 48% |
| Agricultural and Biological Sciences | 19 | 7% |
| Nursing and Health Professions | 14 | 5% |
| Neuroscience | 9 | 3% |
| Biochemistry, Genetics and Molecular Biology | 8 | 3% |
| Other | 28 | 10% |
| Unknown | 69 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 50. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 November 2021.
All research outputs
#836,796
of 25,374,917 outputs
Outputs from The Lancet
#6,788
of 42,665 outputs
Outputs of similar age
#5,665
of 206,326 outputs
Outputs of similar age from The Lancet
#79
of 519 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 42,665 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 67.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,326 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 519 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.